Haleon plc (HLN) is a robust and progressive company with a key business objective of delivering substantial shareholder returns through a commitment to high standards of performance and business conduct. Respected for its strategic, operational, and financial expertise, Haleon operates in a diverse array of sectors including retail, airlines, and leisure.
Haleon is headquartered in London with a strong reputation as a key player in the global market. Its international presence reflects its mission of delivering value-added services to its customers, irrespective of geographical location, with a strong focus on the European, American, and Asian markets.
One of Haleon's major strengths is its decision to compete not only on the basis of scale but also on the ability to deliver high-quality services. A diverse portfolio of business operations and a global footprint provide Haleon with the ability to attain economies of scale and scope, enabling it to offer competitive prices while maintaining high standards of service.
Haleon's success lies in its ability to effectively manage and grow diverse business operations. The company’s leadership fostils a culture of innovation, continuous improvement, and learning, which are core dimensions of Haleon's business strategy. With an emphasis on operational efficiency and cost-effectiveness, Haleon is able to deliver strong financial performance, thereby increasing shareholder returns.
Safety and sustainability are prime concerns for Haleon. The company is committed to operating responsibly, ensuring its businesses run in an environmentally-conscious and sustainable manner. Haleon understands the importance of protecting the environment and the communities it operates in, and integrates its best practices across its value chain to ensure a sustainable business model.
Haleon's business is underpinned by a robust financial position. Its balance sheet strength is a reflection of its sound financial management and disciplined capital allocation strategies, enabling it to pursue strategic investments and growth opportunities.
In terms of corporate governance, Haleon places a strong emphasis on transparency and accountability, evident in their report delivery to shareholders and the wider market. The Board of Directors consists of experienced professionals from diverse backgrounds, ensuring a range of perspectives on decision making and maintaining the highest standards of governance.
The success of Haleon is a testament to its strategic business model, financial strength, and commitment to delivering high-quality services to its customers. Haleon continues to navigate the economic landscape with resilience, guided by a clear vision and strategic direction, and is positioned for continued growth and success into the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
UBS analysts predict that Haleon, the consumer healthcare group, will likely reduce its 2026 organic sales growth guidance due to a subdued third quarter and uncertain outlook for the upcoming cough and cold season. The bank revised its organic sales growth forecast for Haleon down to 3.1% from 3.4% but maintained its adjusted earnings per share forecast. This potential guidance cut reflects the difficulty in forecasting sales in seasonal categories, which could impact full-year growth.
Deutsche Bank has reaffirmed its 'sell' rating on Haleon PLC, maintaining a 320p price target. Analyst Tom Sykes expects slower organic sales growth for the consumer health group, particularly in North America, and notes that gains from a Walmart shelf reset are being offset by weaker online sales and channel shifts. The bank suggests that a reliance on seasonal boosts and reversing currency effects point to continued de-rating for Haleon.
Haleon (LON: HLN) shares have experienced a Death Cross, with the 50-day moving average falling below the 200-day moving average at Tuesday's close. This technical indicator suggests a weakening of recent trading trends compared to the past year. This marks the first recorded Death Cross for Haleon, accompanied by higher-than-average trading volume.
Haleon is targeting users of GLP-1 weight-loss drugs like Wegovy and Zepbound to drive growth in the U.S. market. By strategically placing products that address common side effects of these drugs in stores like CVS, Haleon has seen a significant increase in per-store sales. While this strategy offers a promising new revenue stream and helps strengthen brands like Advil, its overall impact on Haleon's group-level revenue growth remains to be fully seen.
Alan Stewart, Senior Independent Non-Executive Director at Haleon plc, has acquired 242 ordinary shares through a dividend reinvestment plan. The transaction occurred on September 17, 2026, on the London Stock Exchange at a price of A33.378619 per share. This mandatory disclosure under UK Market Abuse Regulation highlights a routine insider shareholding change for the consumer health company.
Haleon, the maker of Advil and TUMS, has seen a boost in U.S. sales by strategically targeting consumers using GLP-1 weight-loss drugs. The company is collaborating with retailers like CVS Pharmacy to place its products, which alleviate common side-effects of these drugs, in dedicated "GLP-1 destination sets" and regular aisles. This dual placement strategy has resulted in a 24% sales lift per store for Haleon, capitalizing on the growing number of Americans using weight-loss medications.
Haleon Plc (HLN) is showing weak near and mid-term sentiment with a neutral long-term outlook, operating within a mid-channel oscillation pattern. The analysis identifies an exceptional 23.7:1 risk-reward setup, targeting a 7.9% gain against a 0.3% risk. Institutional trading strategies are provided, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Haleon PLC (HLN) shares fell by 2.30% to £3.58 on Thursday, despite a generally favorable trading session for the stock market, with the FTSE 100 Index (UKX) rising 0.70%. The company's stock closed 14.06% below its 52-week high of £4.16, which was reached on February 18th.
Haleon PLC (HLN) saw its shares rise by 1.85% to £3.70 on Monday, outperforming the broader market as the FTSE 100 Index also increased. Despite this gain, the company's stock remains 11.13% below its 52-week high of £4.16, which was reached on February 18th.